脂肪组织炎性反应的研究进展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (7): 1052-1055.

脂肪组织炎性反应的研究进展

舒凤, 王梦伊, 张世武, 李倩竹, 张伟华^*

哈尔滨医科大学病理生理学教研室, 黑龙江哈尔滨 150080

收稿日期:2020-07-06 修回日期:2020-10-10 出版日期:2021-07-05 发布日期:2021-06-17
通讯作者: *zhangwh116@126.com
基金资助:
国家自然科学基金(81970317,81970411)

Research progress of inflammatory response of adipose tissue

SHU Feng, WANG Meng-yi, ZHANG Shi-wu, LI Qian-zhu, ZHANG Wei-hua^*

Department of Pathophysiology, Harbin Medical University, Harbin 150080, China

Received:2020-07-06 Revised:2020-10-10 Online:2021-07-05 Published:2021-06-17
Contact: *zhangwh116@126.com

摘要/Abstract

摘要： 本文探讨了与脂肪组织炎性反应相关的脂质介质,促炎介质:环氧合酶衍生的二十烷类化合物(如前列腺素);促炎性反应消退介质:由ω-6-多不饱和脂肪酸产生的脂氧素,以及由ω-3-多不饱和脂肪酸产生的消退素等。炎性反应的治疗不应局限于急性级联拮抗剂或抑制剂的使用,而应扩大到考虑炎性反应消退阶段诱导剂或激动剂的巨大治疗潜力。

关键词: 肥胖, 脂肪组织, 急性炎性反应, 消退

Abstract: This review reported lipid mediators associated with inflammatory responses in adipose tissue, pro-inflammatory mediators: eicosane compounds derived from cyclooxy-genase (e.g. prostaglandins); Pro-resolving mediators: lipoxins produced by omega-6 polyunsaturated fatty acids, and resolvins produced by omega-3 polyunsaturated fatty acids. The treatment of inflammatory responses should not be limited to the use of acute cascade antagonists or inhibitors, but should be expanded to take into account the great therapeutic potential of inducers or agonists in the inflammatory resolution phase.

Key words: obesity, adipose tissue, acute inflammatory response, resolution

中图分类号:

R363.1

舒凤, 王梦伊, 张世武, 李倩竹, 张伟华. 脂肪组织炎性反应的研究进展[J]. 基础医学与临床, 2021, 41(7): 1052-1055.

SHU Feng, WANG Meng-yi, ZHANG Shi-wu, LI Qian-zhu, ZHANG Wei-hua. Research progress of inflammatory response of adipose tissue[J]. Basic & Clinical Medicine, 2021, 41(7): 1052-1055.

参考文献

[1]GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health effects of overweight and obesity in 195 countries over 25 years[J]. N Engl J Med, 2017,377:13-27.
[2]Tang EH, Cai Y, Wong CK, et al. Activation of prostaglandin E2-EP4 signaling reduces chemokine production in adipose tissue[J]. J Lipid Res, 2015,56:358-368.
[3]Chan PC, Hsiao FC, Chang HM, et al. Importance of adipocyte cyclooxygenase-2 and prostaglandin E2-prosta-glandin E receptor 3 signaling in the development of obesity-induced adipose tissue inflammation and insulin resistance[J]. FASEB J, 2016,30:2282-2297.
[4]Hu X, Cifarelli V, Sun S, et al. Major role of adipocyte prostaglandin E2 in lipolysis-induced macrophage recruitment[J]. J Lipid Res, 2016,57:663-673.
[5]Börgeson E, McGillicuddy FC, Harford KA, et al. Lipoxin A4 attenuates adipose inflammation[J]. FASEB J, 2012,26:4287-4294.
[6]Börgeson E, Johnson AM, Lee YS, et al. Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease[J]. Cell Metab, 2015,22:125-137.
[7]Arita M, Ohira T, Sun YP, et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation[J]. J Immunol, 2007,178:3912-3917.
[8]Titos E, Rius B, González-Périz A, et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype[J]. J Immunol, 2011,187:5408-5418.
[9]Titos E, Rius B, López-Vicario C, et al. Signaling and immunoresolving actions of resolvin D1 in inflamed human visceral adipose tissue[J]. J Immunol, 2016,197:3360-3370.
[10]Chiurchiù V, Leuti A, Dalli J, et al. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses[J]. Sci Transl Med, 2016,8:353ra111. doi: 10.1126/scitranslmed.aaf7483.
[11]Sulciner ML, Serhan CN, Gilligan MM, et al. Resolvins suppress tumor growth and enhance cancer therapy[J]. J Exp Med, 2018,215:115-140.
[12]Serhan CN, Gotlinger K, Hong S, et al. Anti-inflam-matory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes[J]. J Immunol, 2006,176:1848-1859.
[13]Serhan CN, Dalli J, Colas RA, et al. Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome[J]. Biochim Biophys Acta, 2015,1851:397-413.
[14]Aursnes M, Tungen JE, Colas RA, et al. Synthesis of the 16S,17S-epoxyprotectin intermediate in the biosynthesis of protectins by human macrophages[J]. J Nat Prod, 2015,78:2924-2931.
[15]Dalli J, Colas RA, Quintana C, et al. Human sepsis eicosanoid and proresolving lipid mediator temporal profiles: correlations with survival and clinical outcomes[J]. Crit Care Med, 2017,45:58-68.
[16]Serhan CN. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms[J]. FASEB J, 2017,31:1273-1288.
[17]Serhan CN, Yang R, Martinod K, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions[J]. J Exp Med, 2009,206:15-23.
[18]Serhan CN, Dalli J, Karamnov S, et al. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain[J]. FASEB J, 2012,26:1755-1765.
[19]Deng B, Wang CW, Arnardottir HH, et al. Maresin biosynthesis and identification of maresin 2, a new anti-inflammatory and pro-resolving mediator from human macrophages[J]. PLoS One, 2014,9:e102362.doi: 10.1371/journal.pone.0102362.
[20]Dalli J, Vlasakov I, Riley IR, et al. Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages[J]. Proc Natl Acad Sci U S A, 2016,113:12232-12237.
[21]Francos-Quijorna I, Santos-Nogueira E, Gronert K, et al. Maresin 1 promotes inflammatory resolution, neuroprotection, and functional neurological recovery after spinal cord injury[J]. J Neurosci, 2017,37:11731-11743.